Search
forLearn
5 / 801 resultslearn retinoic acid
learn Setipiprant
learn nicotinamide
learn 18β-glycyrrhetinic acid
Research
5 / 1000+ results
research Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility
Lifestyle changes improve metabolism and fertility in overweight PCOS patients; anti-obesity drugs show potential but need more research.
research Hepatotoxicity Secondary to A Drug to Lose Weight, "Orlistat": to take into Account as a Differential Diagnosis
The weight loss drug Orlistat can cause liver damage and should be used with caution, especially in those with liver or kidney issues.
research Post-Finasteride Syndrome – When will we Get the Courage to Fight the Dictating Pharma Industry – Despite Awareness of “Sexual, Neurological and Metabolic Side Effects in Young Men for Over a Decade”
Finasteride, a drug used for certain conditions, can cause serious side effects like sexual dysfunction, suicidal thoughts, and increased diabetes risk, and there's a need for more awareness and research about these effects.
research Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
research Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study
Women with PCOS have a higher risk of diabetes and heart problems, especially when they get older.
Community Join
5 / 1000+ resultscommunity EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community Allergan recruiting for Setipiprant trial in the US
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
community P-1075: a BETTER version of Minoxidil
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Quitting Alfatradiol after 4 months
The user stopped using Alfatradiol after 4 months due to no hair improvement and side effects like dry scalp and gallbladder pain. They are considering trying topilutamide, which is suggested as an alternative.